Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine for routine pediatric vaccination programs in Japan.
Masayoshi ShinjohKanae TogoTomoyuki HayamizuNaohiro YonemotoJunko MoriiJohnna E PerdrizetKazumasa KameiPublished in: Expert review of vaccines (2024)
As a pediatric vaccine, PCV20 was dominant over PCV13 regardless of the study perspective.